Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer

Frontiers in Immunology(2020)10.3389/fimmu.2020.581301Source: DataRank Database

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer is a research paper published in Frontiers in Immunology (2020). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.43)OA: goldTopics (87)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Madhura Satish Bhave,Hideo Yagita∥ORCID,Susanna Cardell ORCID,Ying Wang ORCID

Live enrichment

PubMed:33193386 OpenAlex:https://openalex.org/W3094212911

Swedish Cancer Society

Grant: unidentified

unidentified

FWCI

1.43

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.581301/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.581301/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.581301/full

journalhttps://doi.org/10.3389/fimmu.2020.581301

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33193386

Fields of Study

Immune Cell Function and InteractionT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers0301 basic medicine03 medical and health sciences0303 health sciencesAdenomatous Polyposis Coli ProteinAnimalsAntibodies, BlockingColonic NeoplasmsFemaleGalactosylceramidesHumansIntestinal MucosaIntestinal PolypsMacrophagesMaleMiceMice, Inbred C57BLMice, Mutant StrainsNatural Killer T-CellsNeoplasms, ExperimentalProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryTh1 Cells

MeSH Terms

AnimalsColonic NeoplasmsFemaleGalactosylceramidesHumansIntestinal MucosaIntestinal PolypsMacrophagesMaleMice, Inbred C57BLMice, Mutant StrainsNeoplasms, ExperimentalTh1 CellsAntibodies, BlockingAdenomatous Polyposis Coli ProteinT-Lymphocytes, RegulatoryMiceNatural Killer T-CellsProgrammed Cell Death 1 Receptor

Keywords

Granzyme BDownregulation and upregulationCancer researchCancerCD1DImmune systemBlockadeColorectal cancerMedicineT cellMelanomaImmunologyReceptorBiologyNatural killer T cellInternal medicineMaletumorAdenomatous Polyposis Coli ProteinProgrammed Cell Death 1 ReceptorGalactosylceramidesNKT (natural killer T) cellsT-Lymphocytes, RegulatoryMicePD-1check-point blockadeAnimalsHumansIntestinal MucosaAntibodies, BlockingintestineMacrophagesIntestinal PolypsNeoplasms, ExperimentalRC581-607Th1 CellsMice, Mutant Strainsalpha-galacosylceramideMice, Inbred C57BLColonic NeoplasmsNatural Killer T-CellsFemaleImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being